Effectiveness of LASER in pigmented purpuric dermatosis – a placebo-controlled split-limb trial
Phase 1
- Conditions
- Health Condition 1: L817- Pigmented purpuric dermatosis
- Registration Number
- CTRI/2024/03/064313
- Lead Sponsor
- Bankura Sammilani Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Age more than 18 years to 80 years.
Pigmented purpuric dermatosis patients who have not received any treatment since 1 month.
Pigmentation present bilaterally on the lower limbs.
Exclusion Criteria
Pregnant and lactating women.
Patients having pigmented purpuric dermatosis at sites other than lower limbs.
Those having any skin disease other than pigmented purpuric dermatosis on the lower limb(s).
Patients with psychiatric disorders.
Participation in any clinical trial within the last 3 months.
Non-consenting patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The Q switched neodymium doped yttrium aluminum garnett laser will be more effcetive in reducing pigmentation of pigmented purpuric dermatosis , compared to placebo on the basis of decline in skin hyperpigmentation index.Timepoint: 16 weeks
- Secondary Outcome Measures
Name Time Method The safety of Q switched neodymium doped yttrium aluminum garnett laser will be evaluated in patients with pigmented purpuric dermatosis , compared to placebo on the basis of adverse events noted.Timepoint: 16 weeks